Enhanced bioavailability of danazol nanosuspensions by wet milling and high-pressure homogenization
article
OA: hybrid
CC0
⤵ 1 in-corpus citation
AI-generated summary
Danazol nanosuspensions prepared by wet milling and high-pressure homogenization exhibited enhanced dissolution velocity and oral bioavailability in rats due to nanocrystalline formation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
INTRODUCTION: The majority of drugs obtained through synthesis and development show poor aqueous solubility and dissolution velocity, resulting in reduced bioavailability of drugs. Most of these problems arise from formulation-related performance issues, and an efficient way to overcome these obstacles and to increase dissolution velocity is to reduce the particle size of drug substances to form drug nanosuspensions. MATERIALS AND METHODS: performances of the prepared nanosuspensions, dissolution velocity, and bioavailability studies were performed. RESULTS: Particle size and zeta potential analysis showed the formation of nanosized particles with a negative charge on the surface. XRD depicted the nanocrystalline nature of danazol with low diffraction intensities. With increased surface area and saturation solubility, the nanosuspensions showed enhanced dissolution velocity and oral bioavailability in rats when compared to the bulk danazol suspension. CONCLUSIONS: The results suggest that the preparation of nanosuspensions by WM or HPH is a promising approach to formulate new drugs or to reformulate existing drugs with poorly water-soluble properties.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs 1995
- A liquid chromatographic method for the determination of danazol in human serum 1990
- Formulation and Performance of Danazol Nano-crystalline Suspensions and Spray Dried Powders 2014
Cited by (1)
- Danazol 2022
References (41)
- A liquid chromatographic method for the determination of danazol in human serum via openalex
- Formulation and Performance of Danazol Nano-crystalline Suspensions and Spray Dried Powders via openalex
- Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs via openalex
- doi:10.1016/j.ejpb.2005.05.009 via openalex
- doi:10.1016/0022-0248(88)90294-1 via openalex
- doi:10.1016/j.ijpharm.2012.04.043 via openalex
- doi:10.1177/0192623307310946 via openalex
- doi:10.3892/ijo_00000665 via openalex
- doi:10.1023/a:1014276917363 via openalex
- doi:10.1016/j.ejpb.2011.08.006 via openalex
- doi:10.1016/j.ejpb.2011.01.007 via openalex
- doi:10.1023/a:1016177404647 via openalex
- doi:10.1016/s0378-5173(02)00239-9 via openalex
- doi:10.1002/jps.2600821008 via openalex
- doi:10.1211/0022357023691 via openalex
- doi:10.1016/s0928-0987(02)00251-8 via openalex
- W2675005138 via openalex
- doi:10.1016/0378-5173(95)00008-7 via openalex
- doi:10.1016/j.ijpharm.2006.04.012 via openalex
- doi:10.1007/bf01209119 via openalex
- doi:10.1023/b:pham.0000048196.61887.e5 via openalex
- doi:10.1248/cpb.57.1050 via openalex
- doi:10.1016/j.addr.2012.09.019 via openalex
- doi:10.1016/j.ijpharm.2010.12.027 via openalex
- doi:10.1016/j.ejpb.2007.05.009 via openalex
- doi:10.1016/s1056-8719(00)00107-6 via openalex
- doi:10.1111/j.2042-7158.2011.01279.x via openalex
- doi:10.1002/pssa.2211240228 via openalex
- doi:10.1016/j.ejpb.2004.03.022 via openalex
- doi:10.1007/s12030-009-9028-2 via openalex
- doi:10.1016/s0169-409x(00)00129-0 via openalex
- doi:10.1023/a:1016212804288 via openalex
- doi:10.1016/s0169-409x(00)00103-4 via openalex
- doi:10.1016/s0378-5173(03)00029-2 via openalex
- doi:10.1080/03639040802005024 via openalex
- doi:10.1016/s0378-5173(97)00367-0 via openalex
- doi:10.1016/s0022-3093(01)00788-8 via openalex
- doi:10.1021/ja02086a003 via openalex
- doi:10.1016/j.ijpharm.2011.08.033 via openalex
- doi:10.1016/j.ijpharm.2007.05.049 via openalex
- doi:10.1002/(sici)1520-6017(200004)89:4<429::aid-jps1>3.0.co;2-j via openalex
Cited by (1)
- Danazol 2022
Source provenance
- openalex
- last seen: 2026-05-11T06:42:59.773506+00:00
License: CC0
· commercial use OK